Albumin is the most abundant protein in human blood plasma — constituting approximately 55-60% of total plasma protein at a concentration of 3.5-5.0 g/dL. It is synthesized exclusively by hepatocytes (liver cells) at a rate of approximately 12-25 grams per day, and it circulates with a half-life of approximately 20 days. Despite being a single protein, albumin performs an extraordinary range of essential functions — from maintaining blood volume to transporting drugs, hormones, and fatty acids to providing antioxidant defense (Fanali et al., 2012, Molecular Aspects of Medicine).
Albumin is so important that its serum concentration is one of the most powerful predictors of clinical outcomes across virtually every disease category — from surgery to cancer to critical illness. Understanding albumin is understanding a protein that sits at the intersection of physiology, clinical medicine, and prognostic science.
Structure and properties
Human serum albumin (HSA) is a 585-amino-acid, 66.5-kDa protein with a characteristic heart-shaped three-dimensional structure consisting of three homologous domains (I, II, and III), each containing two subdomains (A and B). This modular structure creates multiple binding sites for an extraordinary variety of ligands (He & Carter, 1992, Nature).
Key structural properties include: a single free cysteine residue (Cys-34) that provides antioxidant activity; high water solubility and stability over a wide pH range (pH 4-9); a net negative charge at physiological pH — contributing to the Donnan equilibrium across capillary membranes; and remarkable conformational flexibility that allows binding to diverse molecular classes.
Functions of albumin
1. Oncotic pressure maintenance
Albumin's most critical physiological function is maintaining plasma oncotic (colloid osmotic) pressure — the osmotic force that retains fluid within blood vessels. Albumin contributes approximately 75-80% of plasma oncotic pressure (approximately 25 mmHg of the total 28 mmHg). Without adequate oncotic pressure, fluid leaks from capillaries into interstitial tissues — causing edema (Levick & Michel, 2010, Cardiovascular Research).
The Starling equation describes the balance between hydrostatic pressure (pushing fluid out of capillaries) and oncotic pressure (pulling fluid back in). When albumin levels drop (hypoalbuminemia), oncotic pressure decreases — resulting in: peripheral edema (swollen ankles, legs), ascites (fluid accumulation in the abdomen — common in liver cirrhosis), pleural effusions (fluid around the lungs), and pulmonary edema (fluid in the lungs).
2. Transport function
Albumin is the body's primary transport protein, carrying: fatty acids (up to 7 long-chain fatty acid molecules per albumin molecule — the primary transport mechanism for free fatty acids), bilirubin (unconjugated bilirubin is water-insoluble and requires albumin transport to the liver for conjugation), calcium (approximately 40% of serum calcium is albumin-bound — which is why calcium levels must be corrected for albumin concentration), hormones (thyroid hormones, cortisol, testosterone, estradiol), drugs (warfarin, diazepam, phenytoin, ibuprofen — drug binding to albumin affects drug distribution, bioavailability, and half-life), metals (copper, zinc — albumin is the primary zinc transporter), and tryptophan (essential amino acid transport to the brain — relevant to serotonin synthesis) (Kragh-Hansen et al., 2002, Biological & Pharmaceutical Bulletin).
The drug-binding function of albumin has profound pharmacological implications: highly albumin-bound drugs (warfarin is >99% albumin-bound) have a small "free fraction" — the unbound, pharmacologically active portion. In hypoalbuminemia, the free fraction increases — potentially producing drug toxicity at standard doses. This is clinically critical for anticoagulants, anticonvulsants, and benzodiazepines (Benet & Hoener, 2002, Clinical Pharmacology & Therapeutics).
3. Antioxidant defense
Albumin is the most abundant extracellular antioxidant in plasma — accounting for approximately 70% of plasma antioxidant capacity: the Cys-34 thiol group scavenges reactive oxygen species (ROS) and reactive nitrogen species; albumin binds and neutralizes free copper and iron ions (which catalyze ROS formation through Fenton chemistry); and albumin binds and inactivates bilirubin — which, while toxic at high concentrations, functions as an antioxidant at low concentrations (Roche et al., 2008, FEBS Letters).
4. Acid-base buffering
Albumin contributes to blood acid-base buffering through its imidazole side chains (histidine residues), contributing approximately 10% of plasma buffering capacity. Albumin's anionic charge at physiological pH also contributes to the strong ion difference (SID) — a physicochemical determinant of blood pH in the Stewart approach to acid-base physiology (Figge et al., 1991, Critical Care Medicine).
Hypoalbuminemia: causes, consequences, and clinical significance
Hypoalbuminemia (serum albumin < 3.5 g/dL) is one of the most powerful predictors of poor clinical outcomes across virtually every disease category:
Causes
Decreased synthesis: Liver disease (cirrhosis, hepatitis — the liver cannot produce adequate albumin), malnutrition (inadequate amino acid substrate for albumin synthesis), and chronic inflammation (inflammatory cytokines — particularly IL-6 — suppress hepatic albumin synthesis).
Increased loss: Nephrotic syndrome (massive urinary albumin loss — sometimes >10 g/day), protein-losing enteropathy (GI albumin loss), burns (large-surface burns cause massive albumin loss through damaged skin), and hemorrhage.
Redistribution: Sepsis and critical illness (capillary leak syndrome — albumin redistributes from intravascular to interstitial spaces), and post-surgical fluid shifts.
Increased catabolism: Hyperthyroidism, Cushing's syndrome, and cancer cachexia (Don & Kaysen, 2004, Seminars in Dialysis).
Prognostic significance
Serum albumin is one of the strongest independent predictors of mortality: in surgical patients, preoperative albumin < 3.0 g/dL is associated with 2-5x increased risk of surgical complications and mortality (Gibbs et al., 1999, Archives of Surgery); in hospitalized patients, hypoalbuminemia predicts length of stay, ICU admission, and in-hospital mortality; in cancer patients, hypoalbuminemia predicts tumor progression, treatment tolerance, and survival; in dialysis patients, each 1 g/dL decline in albumin increases mortality by approximately 40-50%; and in community-dwelling elderly, low albumin predicts all-cause mortality, cardiovascular events, and functional decline.
Albumin and inflammation: the acute phase response
Albumin is a "negative acute-phase protein" — its synthesis is downregulated during inflammation and infection: inflammatory cytokines (IL-6, TNF-α, IL-1β) suppress hepatic albumin gene transcription; the liver prioritizes synthesis of positive acute-phase proteins (CRP, fibrinogen, haptoglobin) over albumin during inflammatory states; capillary permeability increases during inflammation — causing albumin to leak from the vascular space; and catabolic state of illness increases albumin breakdown (Gabay & Kushner, 1999, New England Journal of Medicine).
This means that low albumin in hospitalized patients often reflects inflammation severity more than nutritional status — a critical clinical distinction that affects treatment decisions.
Clinical applications
Albumin infusion therapy
Human albumin solution (5% iso-oncotic or 25% hyper-oncotic) is used therapeutically for: volume resuscitation in cirrhotic patients with spontaneous bacterial peritonitis (proven mortality benefit — Sort et al., 2009, New England Journal of Medicine), large-volume paracentesis (albumin replacement prevents post-paracentesis circulatory dysfunction), hepatorenal syndrome (albumin + vasopressors), and critically ill patients (the SAFE study demonstrated safety of albumin vs. saline for resuscitation — Finfer et al., 2004, New England Journal of Medicine; the ALBIOS trial showed no overall mortality benefit of albumin targeting in sepsis).
Corrected calcium
Because approximately 40% of serum calcium is albumin-bound, total calcium measurements must be corrected for albumin: Corrected calcium = measured calcium + 0.8 × (4.0 − measured albumin). Without correction, hypoalbuminemia masks hypocalcemia and leads to diagnostic errors.
Drug dosing adjustments
For highly albumin-bound drugs, hypoalbuminemia requires dose adjustments to prevent toxicity: phenytoin levels must be corrected for albumin; warfarin dosing may need reduction in hypoalbuminemia; and benzodiazepine effects may be prolonged.
Albumin is far more than "just a protein." It is a multifunctional molecular workhorse — simultaneously maintaining blood volume, transporting essential molecules, defending against oxidative damage, buffering pH, and serving as one of medicine's most powerful prognostic biomarkers. Understanding albumin is understanding a protein whose clinical significance spans every medical specialty and every hospital ward.
Glycated albumin: an emerging biomarker
Glycated albumin (GA) — albumin modified by non-enzymatic glycation — is gaining traction as a biomarker of short-term glycemic control (reflecting 2-3 weeks of blood glucose, compared to HbA1c's 2-3 months): GA is more accurate than HbA1c in patients with conditions that affect red blood cell lifespan (hemolytic anemias, pregnancy, iron deficiency), GA responds faster to therapeutic changes — useful for monitoring acute glycemic interventions, and GA may better reflect postprandial glucose excursions than HbA1c (Koga & Kasayama, 2010, Endocrine Journal).
Albumin in liver disease: the clinical cornerstone
In liver cirrhosis, albumin takes on outsized clinical importance: albumin level is a component of the Child-Pugh score — the standard classification system for cirrhosis severity; hypoalbuminemia drives ascites (reduced oncotic pressure + portal hypertension → fluid accumulation in the peritoneal cavity); albumin infusion has proven mortality benefit in spontaneous bacterial peritonitis (reducing renal failure and death); long-term albumin infusion (25% solution, 40g biweekly) may improve survival in cirrhotic patients with ascites — the ANSWER trial (Di Pascoli et al., 2019, Lancet); and albumin's anti-inflammatory, antioxidant, and immunomodulatory properties may provide benefits beyond oncotic pressure maintenance in cirrhosis (Bernardi et al., 2020, Gut).
Albumin and the kidney
Albumin has a complex relationship with the kidney: the healthy glomerulus filters approximately 1 gram of albumin daily — virtually all of which is reabsorbed by proximal tubular cells via megalin/cubilin-mediated endocytosis; albuminuria (albumin in the urine) is the hallmark of glomerular damage — microalbuminuria (30-300 mg/day) is an early marker of diabetic nephropathy, hypertensive nephrosclerosis, and cardiovascular disease; proteinuria itself accelerates kidney disease progression — albumin in the renal tubules activates inflammatory pathways in tubular cells; and ACE inhibitors and ARBs reduce albuminuria — which is one mechanism by which they slow kidney disease progression (Abbate et al., 2006, Journal of the American Society of Nephrology).
The albumin-creatinine ratio (ACR)
The urine albumin-to-creatinine ratio (ACR) is one of the most important screening tests in modern medicine: ACR > 30 mg/g = moderately increased albuminuria (formerly "microalbuminuria"); ACR > 300 mg/g = severely increased albuminuria (formerly "macroalbuminuria"); ACR is recommended for annual screening in all diabetic patients and hypertensive patients; it is a component of the KDIGO classification of chronic kidney disease (together with eGFR); and elevated ACR is an independent cardiovascular risk factor — even in the absence of overt kidney disease (KDIGO, 2013, Kidney International Supplements).
Albumin in nutrition assessment
While albumin has traditionally been used as a marker of nutritional status, this interpretation requires nuance: albumin is a negative acute-phase protein — it decreases during inflammation regardless of nutritional intake; albumin's long half-life (20 days) makes it insensitive to short-term nutritional changes; and pre-albumin (transthyretin, half-life 2 days) and retinol-binding protein (half-life 12 hours) reflect more recent nutritional status. Current clinical guidelines recommend interpreting albumin as a marker of overall disease severity and inflammatory status rather than nutritional status alone (Evans et al., 2008, Clinical Nutrition).
Albumin stands as a testament to molecular multitasking at its finest — one protein performing critical functions in oncotic pressure, molecular transport, antioxidant defense, acid-base buffering, and clinical prognostication. It is the protein that clinical medicine cannot do without — and the biomarker whose concentration speaks more loudly about a patient's prognosis than almost any other laboratory value.
Albumin and sepsis: beyond volume expansion
In sepsis, albumin plays multiple roles beyond oncotic pressure: albumin binds endotoxin (bacterial lipopolysaccharide — LPS) — potentially reducing TLR4 activation and downstream inflammatory signaling; albumin scavenges reactive oxygen species produced during sepsis-associated oxidative stress; albumin modulates nitric oxide metabolism — potentially improving microvascular perfusion; and albumin carries sphingosine-1-phosphate (S1P) — a bioactive lipid that maintains endothelial barrier function (Quinlan et al., 2005, Hepatology).
The ALBIOS trial (Caironi et al., 2014, New England Journal of Medicine) found that targeting albumin levels ≥ 3.0 g/dL in sepsis with daily albumin infusions did not reduce 28-day mortality overall — but did show a survival benefit in the subgroup with septic shock, suggesting that albumin's effects may be most important in the most severe cases.
Albumin nanotechnology and drug delivery
Albumin's drug-binding properties have been exploited for drug delivery systems: nab-paclitaxel (Abraxane — albumin-bound paclitaxel) is FDA-approved for breast cancer, non-small cell lung cancer, and pancreatic cancer — exploiting albumin's natural transcytosis pathway (gp60 receptor and SPARC-mediated tumor accumulation) to deliver chemotherapy preferentially to tumors; albumin nanoparticles are being developed for targeted drug delivery across the blood-brain barrier (leveraging FcRn-mediated transcytosis); and albumin fusion proteins (linking therapeutic proteins to albumin) extend drug half-life — exploiting albumin's FcRn-mediated recycling to prolong exposure (Kratz, 2008, Journal of Controlled Release).
The albuminome
The "albuminome" — the complete catalogue of molecules bound to circulating albumin at any given time — has emerged as a rich source of diagnostic biomarkers: albumin-bound fatty acid profiles reflect metabolic status; albumin-carried peptide fragments (the "peptidomics" of the albuminome) may contain cancer biomarkers; albumin post-translational modifications (glycation, oxidation, nitrosylation) reflect chronic disease states; and the albuminome changes characteristic patterns in cancer, sepsis, liver disease, and kidney disease — potentially providing a single-biomarker window into systemic health (Gundry et al., 2007, Molecular & Cellular Proteomics).
Recombinant albumin
Recombinant human albumin — produced in yeast (Saccharomyces cerevisiae) or rice plants (Oryza sativa) — offers an alternative to plasma-derived albumin: eliminating blood-borne pathogen transmission risk, providing consistent quality (no lot-to-lot variation), and enabling unlimited supply. Recombinant albumin is already used in cell culture media and vaccine production — therapeutic use is in clinical development (Chen et al., 2013, BMC Biotechnology).
Albumin may be the most important protein most people have never heard of. It is the master multitasker of the blood — simultaneously maintaining pressure, transporting molecules, defending against oxidation, buffering pH, and predicting outcomes. Its serum concentration distills the complex interplay of liver function, inflammation, nutrition, and disease severity into a single number — making it one of the most information-dense laboratory values in all of medicine.
Albumin and heart failure
Hypoalbuminemia is common in heart failure — affecting 20-40% of patients — and is a strong independent predictor of mortality and hospitalization: mechanisms include hepatic congestion (reduced albumin synthesis), inflammation (IL-6-mediated suppression), and gut edema (protein-losing enteropathy). The relationship is bidirectional: hypoalbuminemia worsens edema (reduced oncotic pressure → fluid extravasation), which worsens heart failure symptoms.
Whether albumin treatment in heart failure improves outcomes is an active research question. Small studies suggest that albumin infusion with diuretics may improve diuresis and reduce edema in diuretic-resistant heart failure — potentially through improved loop diuretic delivery to the kidney (albumin-furosemide complexes) and maintained intravascular volume during diuresis (Jhund & McMurray, 2008, European Journal of Heart Failure).
Albumin and the brain
Albumin has important interactions with the central nervous system: the blood-brain barrier normally excludes albumin from the CNS; when the BBB is disrupted (traumatic brain injury, stroke, neuroinflammation), albumin extravasation into brain tissue activates TGF-β signaling in astrocytes — triggering neuroinflammatory cascades and epileptogenesis; albumin-containing CSF (elevated CSF/serum albumin ratio — the "albumin quotient") is a clinical marker of BBB integrity, used to diagnose multiple sclerosis, meningitis, and other neurological conditions (Friedman et al., 2009, Epilepsia).
The ALIAS trial (Ginsberg et al., 2013, Lancet Neurology) tested high-dose albumin as a neuroprotective agent in acute ischemic stroke — the rationale being albumin's antioxidant and volume-expanding properties. The trial found no benefit, but the concept of albumin-based neuroprotection continues to be explored.
Albumin is the protein that binds everything, buffers everything, transports everything, and predicts everything. In a world of molecular specialists, albumin is the ultimate generalist — and medicine is better for understanding it.
Albumin and COVID-19
Hypoalbuminemia was one of the strongest predictors of severe COVID-19 outcomes: approximately 50-70% of hospitalized COVID-19 patients had albumin < 3.5 g/dL at admission; each 1 g/dL decrease in albumin was associated with approximately 2.5-fold increased risk of mortality; and the mechanisms included IL-6-mediated suppression of albumin synthesis, capillary leak from endothelial injury, and increased catabolism (Huang et al., 2020, Lancet).
Albumin measurement was recommended as a prognostic tool in COVID-19 triage — helping identify patients at highest risk for deterioration. The role of albumin infusion in COVID-19 treatment remains under investigation, with theoretical benefits from oncotic pressure maintenance, antioxidant effects, and endotoxin binding — but no large-scale RCT evidence of mortality benefit as of 2024.
Albumin remains what it has always been: the silent workhorse of the blood, the molecular Swiss army knife of plasma, and one of the most clinically informative biomarkers in all of medicine.
Albumin is nature's original multifunctional protein — simultaneously a molecular porter, an antioxidant sentinel, an oncotic guardian, a pH buffer, and a clinical oracle. Understanding albumin is understanding the molecular infrastructure that keeps the blood — and the body — functional.
Albumin endures — the essential protein of human blood.